Another phase III clinical trial proved that tucidinostat plus exemestane improved median progression-free survival (from 3.8 months to 7.4 months) compared with placebo group in hormone receptor-positive, HER2-negative breast cancer patients [239]. The gene discussed is ERBB2; the disease is breast carcinoma.